Comunicados de prensa Eli Lilly — News Releases Salud y ciencias de la vida — Feed RSS y monitoreo en vivo
PPN World sigue el feed RSS de Eli Lilly — News Releases en tiempo real — 5 comunicados indexados en los últimos 30 días, el más reciente llegó hace 2 d. Síguelo con alertas de búsquedas guardadas, resúmenes con IA y búsqueda de texto completo, o conecta la URL RSS de abajo a tu propio lector.
URL del feed RSS de Eli Lilly — News Releases
https://investor.lilly.com/rss/news-releases.xml?items=10Sobre este feed
Eli Lilly — News Releases forma parte de los más de 1000 feeds de comunicados que PPN World monitorea de forma continua — una fuente en inglés centrada en el sector Salud y ciencias de la vida, clasificada bajo «Estados Unidos» en nuestro índice por país. Cada comunicado se deduplica, se geolocaliza y se enriquece con un resumen de IA, y puedes añadir alertas de búsquedas guardadas sobre cualquier palabra clave que publique. Eli Lilly — News Releases es una fuente especializada de bajo volumen — 5 comunicados en los últimos 30 días: el tipo de fuente que merece una alerta más que un desplazamiento.
Cómo seguir los comunicados de Eli Lilly — News Releases
- Copia la URL del feed RSS de Eli Lilly — News Releases que aparece arriba.
- Pégala en cualquier lector RSS (Feedly, Inoreader, NetNewsWire…) para recibir el feed sin procesar.
- O sigue Eli Lilly — News Releases en PPN World para añadir deduplicación, alertas de búsquedas guardadas y resúmenes con IA en los más de 1000 feeds.
Últimos comunicados de Eli Lilly — News Releases
- Lilly confirms date and conference call for second-quarter 2026 financial results announcementhace 2 d
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that…
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionshace 9 d
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging…
- Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatmenthace 16 d
Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood te…
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapyhace 29 d
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Jo…
- Lilly launches “The Memory Radio Station” across Europe, inviting the public to visually reconstruct fading memories through GenAIhace 29 d
New multi-country campaign launches in Geneva alongside the European Academy of Neurology Congress GENEVA, SWITZERLAND, June 26, 2026 -- Today, Eli Lilly and Company (NYSE: LLY) launches The Memory Ra…
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight managementhace 30 d
A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part D patients b…
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disordershace 30 d
INDIANAPOLIS, June 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage…
- Lilly declares third-quarter 2026 dividendhace 32 d
INDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common s…
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLhace 41 d
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients previously treated with a covalent BTK inhibitor…
Los comunicados más recientes de esta fuente se transmiten en vivo para los miembros de PPN World.